BlackRock Discloses Passive Stake in Assertio Holdings (ASRT)
Ticker: ASRT · Form: SC 13G · Filed: 2024-01-26T00:00:00.000Z
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock owns a piece of Assertio, signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, filed an SC 13G on January 26, 2024, disclosing its ownership of Assertio Holdings, Inc. common stock as of December 31, 2023. This filing indicates BlackRock's passive investment in Assertio, a pharmaceutical company, and is important for investors as it signals a large institutional holder's continued interest, potentially lending stability or credibility to the stock.
Why It Matters
This filing shows that a major institutional investor, BlackRock, holds a significant, passive stake in Assertio Holdings, which can influence investor confidence and stock stability.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of passive ownership by a large institutional investor, indicating no immediate red flags or significant changes in company control.
Analyst Insight
An investor should note BlackRock's passive stake as a sign of institutional interest, but also recognize that a 13G filing doesn't imply active management or a change in company strategy. It's a data point for understanding the shareholder base.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Assertio Holdings, Inc. (company) — the subject company whose stock is being reported
- 0001364742 (company) — Central Index Key (CIK) for BlackRock Inc.
- 0001808665 (company) — Central Index Key (CIK) for Assertio Holdings, Inc.
- December 31, 2023 (date) — the date of the event which requires the filing
- January 26, 2024 (date) — the filing date of the SC 13G
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically designated under Rule 13d-1(b), which indicates passive ownership by an institutional investor.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742, a major financial institution.
Which company's securities are the subject of this filing?
The subject company is Assertio Holdings, Inc., identified by CIK 0001808665, a pharmaceutical preparations company.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Assertio Holdings, Inc. is 04546C205.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
From the Filing
EDGAR Filing Documents for 0001086364-24-004821 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0001086364-24-004821 Filing Date 2024-01-26 Accepted 2024-01-26 17:25:22 Documents 1 Document Format Files Seq Description Document Type Size 1 us04546c2052_012624.txt SC 13G 11531 Complete submission text file 0001086364-24-004821.txt 13363 Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance) Mailing Address 100 S. SAUNDERS ROAD SUITE 300 LAKE FOREST IL 60045 Business Address 100 S. SAUNDERS ROAD SUITE 300 LAKE FOREST IL 60045 (224) 419-7106 Assertio Holdings, Inc. (Subject) CIK : 0001808665 (see all company filings) EIN. : 850598378 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G | Act: 34 | File No.: 005-91515 | Film No.: 24569174 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)